Quantum materials, materials exhibiting physical behavior governed by the laws of quantum mechanics, have proved promising ...
Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key ...
Phase 1b clinical trial of SYX-5219 in adults with moderate to severe atopic dermatitis completes enrollment ahead of scheduleRapid progress in ...
Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative ...
Novel immune reprogramming oral macrocyclic peptides designed for precise modulation of complex biological networks involved in inflammatory, ...
Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.
Bupropion conferred modest reductions in cancer-related fatigue compared with placebo, according to results of a randomized ...
Epicrispr Biotechnologies, a clinical-stage company pioneering epigenetic therapies, today announced new interim data from its ongoing open-label Phase 1/2 first-in-human study of EPI-321 in ...
A new approach for identifying signs of hidden awareness in people who cannot speak or move after severe brain injury has ...
Top line data readout expected in late Q3/early Q4; INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase ...
In adolescents, the most common adverse events (occurring in =5% of ML-004-treated adolescents and at least twice the rate of placebo) were headache (13.7% vs. 3.9%), somnolence (11.8% vs. 0%), nausea ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results